Mirdametinib for brain and nervous system tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and in fairly good overall health (able to care for yourself with minimal help)
- Have blood counts, kidney function, and liver function that are adequate for treatment
- Have a heart that pumps blood normally and no serious active heart disease in the past 6 months
- No active infections, pregnancy, or severe medical conditions that would interfere with the trial
- If you are a woman who could become pregnant, you must use birth control during and for 6 weeks after treatment
- Your tumor must have specific genetic mutations (MAPK pathway for neurohistiocytosis, or NF1 for glioma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
This trial tests a drug called mirdametinib, alone or combined with radiation, to treat high-grade gliomas (aggressive brain or spinal cord tumors) in people with neurofibromatosis type 1 (NF1) or those whose tumors have NF1 gene changes. The drug targets a specific pathway that may help slow or stop these tumors from growing.
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.